Latest Lead News

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Altair Minerals has acquired a controlling interest in the expansive Greater Oko gold project in Guyana, positioning itself as the country’s leading gold explorer. The company has initiated a large-scale geochemical program and plans drilling campaigns to unlock the project’s significant potential.

Mad Paws Holdings reported a robust September quarter with 14% revenue growth and a successful divestment of Pet Chemist, while advancing its acquisition scheme with Rover Group.

Carnegie Clean Energy marked steady progress in Q3 2025, hitting key manufacturing milestones for its CETO wave energy system in Spain, securing €4 million in EU funding, and raising $2.1 million from shareholders to fuel commercialisation efforts.

Clara Resources upgrades the Ashford Coking Coal Project resource classification and raises $1.6 million to fund a critical drilling program, while reviewing strategic options for its Kildanga Nickel/Cobalt asset.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

ABx Group Limited reports strong progress in rare earth extraction and clean chemical production, backed by strategic investments and a recent $3 million capital raise.

Constellation Technologies reports solid first-quarter progress driven by strong demand for its Callisto Food Safety System and new handheld temperature device, alongside promising integration projects and steady revenue.

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Golden Horse Minerals has raised A$35 million through a strongly supported placement to accelerate exploration and development at its Southern Cross Gold Project in Western Australia.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Apollo Minerals reports encouraging exploration results from its Gabon projects, highlighting significant gold intercepts at Salanie and a substantial zinc-lead target at Kroussou, while navigating funding constraints and ongoing legal challenges in Europe.